NO20045274L - Kombinasjon av angiotensin II reseptorblokker og beta-blokker for sekundaer forebyggelse av myokardialt infarkt - Google Patents

Kombinasjon av angiotensin II reseptorblokker og beta-blokker for sekundaer forebyggelse av myokardialt infarkt

Info

Publication number
NO20045274L
NO20045274L NO20045274A NO20045274A NO20045274L NO 20045274 L NO20045274 L NO 20045274L NO 20045274 A NO20045274 A NO 20045274A NO 20045274 A NO20045274 A NO 20045274A NO 20045274 L NO20045274 L NO 20045274L
Authority
NO
Norway
Prior art keywords
blocks
combination
myocardial infarction
angiotensin
beta
Prior art date
Application number
NO20045274A
Other languages
English (en)
Norwegian (no)
Inventor
Robert M Califf
Malcom Macnab
John J V Mcmurray
Marc A Pfeffer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20045274L publication Critical patent/NO20045274L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20045274A 2002-05-17 2004-12-01 Kombinasjon av angiotensin II reseptorblokker og beta-blokker for sekundaer forebyggelse av myokardialt infarkt NO20045274L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38154802P 2002-05-17 2002-05-17
PCT/EP2003/005198 WO2003097099A1 (en) 2002-05-17 2003-05-16 Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction

Publications (1)

Publication Number Publication Date
NO20045274L true NO20045274L (no) 2004-12-01

Family

ID=29550143

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045274A NO20045274L (no) 2002-05-17 2004-12-01 Kombinasjon av angiotensin II reseptorblokker og beta-blokker for sekundaer forebyggelse av myokardialt infarkt

Country Status (15)

Country Link
US (1) US20060014839A1 (pl)
EP (1) EP1509248A1 (pl)
JP (1) JP2005531558A (pl)
KR (1) KR20050000556A (pl)
CN (1) CN1662256A (pl)
AU (1) AU2003240670A1 (pl)
BR (1) BR0311292A (pl)
CA (1) CA2486121A1 (pl)
IL (1) IL165182A0 (pl)
MX (1) MXPA04011428A (pl)
NO (1) NO20045274L (pl)
PL (1) PL373202A1 (pl)
RU (1) RU2004137109A (pl)
WO (1) WO2003097099A1 (pl)
ZA (1) ZA200409200B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
EP1908469A1 (en) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
WO2010008244A2 (ko) * 2008-07-18 2010-01-21 한올제약주식회사 약제학적 제제
US8110185B2 (en) * 2008-10-03 2012-02-07 St. Michael's Hospital Method for preventing and treating cardiovascular diseases with BRCA1
JO3350B1 (ar) * 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
CN103735548B (zh) * 2014-01-23 2015-02-04 南方医科大学南方医院 奥美沙坦酯用于制备预防急性心肌梗死并发症心脏破裂的药物的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9708336A (pt) * 1996-03-29 1999-08-03 Smithkline Beecham Corp Diidrato de eprosartan e processo para sua produção e formulação
IL144216A0 (en) * 1999-01-26 2002-05-23 Novartis Ag Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
AR032758A1 (es) * 2000-07-19 2003-11-26 Novartis Ag Sales valsartan, un proceso para su fabricacion, composiciones farmaceuticas y el uso de dichas sales para la preparacion de medicamentos

Also Published As

Publication number Publication date
EP1509248A1 (en) 2005-03-02
MXPA04011428A (es) 2005-02-14
CA2486121A1 (en) 2003-11-27
RU2004137109A (ru) 2005-10-10
AU2003240670A1 (en) 2003-12-02
ZA200409200B (en) 2006-11-29
BR0311292A (pt) 2005-04-26
PL373202A1 (pl) 2005-08-22
KR20050000556A (ko) 2005-01-05
IL165182A0 (en) 2005-12-18
US20060014839A1 (en) 2006-01-19
CN1662256A (zh) 2005-08-31
WO2003097099A1 (en) 2003-11-27
JP2005531558A (ja) 2005-10-20

Similar Documents

Publication Publication Date Title
BR0312785A (pt) Tratamento de desordens relacionadas a tnf(alfa)
NO20024921L (no) Kombinasjon av organiske forbindelser
GB2392154B (en) Protein Kinase Inhibitors
GB2398781B (en) Kinase inhibitors
HRP20120004T1 (en) Dipeptidyl peptidase inhibitors for treating diabetes
AR040014A1 (es) Combinacion de compuestos organicos
MY150740A (en) Low dose methods for treating disorders in which tnf? activity is detrimental
TW200510349A (en) Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
NO20034549L (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
AR051618A1 (es) Comprimido bicapa y metodo
TNSN07312A1 (en) Combination of organic compounds
WO2005011586A3 (en) Treatment and preventi0n of cardiovascular events
NO20051600L (no) 1,4-disubstituerte piperidinderivater og anvendelse derav som 11-betaHSD1 inhibitorer
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
WO2005084654A3 (en) Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
MX340217B (es) Metodo para el tratamietno y bioensayo que involucra el factor de inhibicion de migracion de macrofagos (mif), como un factor de depresion del miocardio, derivado del corazon.
NO20045274L (no) Kombinasjon av angiotensin II reseptorblokker og beta-blokker for sekundaer forebyggelse av myokardialt infarkt
SE0201940D0 (sv) New combination II
WO2004075856A3 (en) Adenosine a1 receptor antagonist for the treatment of cardiac and renal diseases
EE05235B1 (et) Kompositsiooni, mis inhibeerib LT β ja selle retseptori vahelist toimet, kasutamine
MX2007004020A (es) Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica.
NO20054216L (no) Anvendelse av dipyridamol i kombinasjon med acetylsalisylsyre og en angiotensin II antagonist for forhindring av slag
EA200301197A1 (ru) Композиции селективных ингибиторов циклооксигеназы-2 и облучение для ингибирования или профилактики сердечно-сосудистого заболевания
NZ535199A (en) Use of an inhibitor or antagonist against tissue factor